Jane Street’s Kyverna Therapeutics KYTX Stock Holding History

Jane Street’s Portfolio KYTX Stock Details KYTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$154K	Sell	17,314 -86,900	-83%	-$771K	﹤0.01%	10325
2026 Q1	$899K	Sell	104,214 -77,879	-43%	-$649K	﹤0.01%	6745
2025 Q4	$1.71M	Sell	182,093 -16,758	-8%	-$124K	﹤0.01%	5104
2025 Q3	$1.19M	Buy	198,851 +111,082	+127%	+$444K	﹤0.01%	5929
2025 Q2	$269K	Buy	+87,769	New	+$217K	﹤0.01%	8049
2024 Q4	–	Sell	-39,193	Closed	-$192K	–	10791
2024 Q3	$192K	Buy	39,193 +17,215	+78%	+$133K	﹤0.01%	8675
2024 Q2	$165K	Sell	21,978 -15,063	-41%	-$230K	﹤0.01%	8524
2024 Q1	$920K	Buy	+37,041	New	+$1.03M	﹤0.01%	5569

Other funds holding KYTX

GGI

GordonMD Global Investments Beverely Hills, California $207M AUM

Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

IHG

Insight Holdings Group New York $1.32B AUM 1.62% 1-Year Est. Return

Jane Street's KYTX Position: Q2 2026 in Review

Jane Street reduced its Kyverna Therapeutics (KYTX) stake by 83% in Q2 2026, selling an estimated $771K and leaving 17,314 shares worth $154K. The position accounts for ﹤0.01% of the portfolio, ranked #10325.

Jane Street first reported a position in KYTX in Q1 2024 and has held it in 8 quarters since. The position peaked at $1.71M in Q4 2025. 120 funds tracked by Wall St. Rank hold KYTX as of Q2 2026.

Jane Street held 17,314 shares of Kyverna Therapeutics worth $154K as of Q2 2026.
Jane Street sold 86,900 Kyverna Therapeutics shares in Q2 2026, an estimated $771K.
Kyverna Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q2 2026, its #10325 holding.
Jane Street first reported a position in Kyverna Therapeutics in Q1 2024 and has held it in 8 quarters since.
Jane Street's Kyverna Therapeutics position peaked at $1.71M in Q4 2025.
120 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.